Modes of coordination for health technology adoption: Health Technology Assessment agencies and Group Procurement Organizations in a polycentric regulatory regime

被引:4
|
作者
Miller, Fiona A. [1 ]
Lehoux, Pascale [2 ]
Rac, Valeria E. [3 ,4 ]
Bytautas, Jessica P. [1 ]
Krahn, Murray [4 ,5 ]
Peacock, Stuart [6 ,7 ]
机构
[1] Univ Toronto, Inst Hlth Policy Management & Evaluat, 155 Coll St,4th Floor, Toronto, ON M5T 3M6, Canada
[2] Univ Montreal IRSPUM, Inst Publ Hlth Res, Dept Hlth Management Evaluat & Policy, CP 6128,Succ Ctr Ville Montreal, Montreal, PQ H3C 3J7, Canada
[3] Univ Hlth Network, Toronto Gen Hosp Res Inst, Ted Rogers Ctr Heart Res, Peter Munk Cardiac Ctr, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada
[4] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto Gen Hosp, Eaton Bldg,10th Floor,Room 248,200 Elizabeth St, Toronto, ON M5G 2C4, Canada
[5] Univ Hlth Network, Toronto Gen Hosp Res Inst, Toronto Hlth Econ & Technol Assessment Collaborat, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada
[6] British Columbia Canc Agcy, Canadian Ctr Appl Res Canc Control ARCC, Canc Control Res, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada
[7] Simon Fraser Univ, Fac Hlth Sci, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada
基金
加拿大健康研究院;
关键词
Health policy; Regulatory regime; Group purchasing; Procurement; Governance; Healthcare decision making; Health technology assessment; COST-EFFECTIVENESS ANALYSIS; GOVERNANCE PERSPECTIVE; DECISION-MAKING; INSTITUTIONS; ENGLAND; HTA;
D O I
10.1016/j.socscimed.2020.113528
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The challenge of novel and high cost health technologies has encouraged the growth of regulatory agencies such as Health Technology Assessment (HTA) organizations and Group Procurement Organizations (GPO). Yet the existence of several agencies in the same polycentric regulatory regime raises questions about whether and how their work can be coordinated. Drawing on a case study of GPOs and HTA agencies across four provinces in Canada, involving document review and key informant interviews (n = 44) conducted between 2013 and 2016, we explore the separate evolution of these agencies, emerging connections between them for non-drug technologies, and the organizational processes and evaluative judgments that underpin coordination efforts. HTA agencies and GPOs developed separately; connections emerged recently in three provinces and suggest four modes of coordination. One mode aligns most closely with that recommended by health economists and HTA practitioners, whereby HTA precedes procurement, with coverage decisions informing technology acquisition. The second mode is a version of the first, where procurement refers cases to HTA for coverage or technology management support; unlike the first, it recognizes procurement's evaluative strengths. Yet both the first and second modes focus on exceptional cases and will be infrequent. The third mode is more systemic, reflecting a generalized complementary of purpose as public agencies. HTA could support GPOs in contested technology acquisition efforts through timely and responsive input, while procurement could expand HTA's impact and inform HTA's growing interest in responsible innovation and environmental sustainability. The final mode is non-coordination, reflecting the potential for agencies to occupy quite distinct regulatory niches within the same regime. We conclude that consistency and convergence around a single model of resource allocation is not inevitable; nor is it necessary for coordinated effort. Thus, where differences in regulatory practice and epistemology persist, mutual accommodation and shared learning may prove most productive.
引用
收藏
页数:9
相关论文
共 50 条